RT Journal Article
T1 Citotoxicidad diferencial según el régimen de quimioterapia contra las células madre del cáncer de páncreas: estudio preliminar in vitro
T2 Differential chemotherapeutic regimen cytotoxicity against pancreatic cancer stem cells: a preliminary in vitro study
A1 Doello, Kevin
A1 Quinonero, Francisco J.
A1 Perazzoli, Gloria
A1 Gago, Lidia
A1 Chico, Mari Angeles
A1 Mesas, Cristina
K1 Pancreatic cancer
K1 cancer stem cells
K1 chemoresistance
K1 chemotherapeutic protocols
K1 personalized therapy
K1 Adenocarcinoma
K1 Resistance
AB Introduction: Pancreatic cancer treatment in advanced stages is based on different chemotherapy regimens. Cancer stem cells are responsible for tumor chemoresistance and recurrence in adjuvant and metastatic settings. The objective of this article was to evaluate how these chemotherapeutic regimens affect the proportion of cancer stem cells and the expression of stemness markers.Method: We used the pancreatic adenocarcinoma cell line PANC-1 as a model to apply different chemotherapeutic protocols (monotherapy and combined therapy) using 5-Fluorouracil, Oxaliplatin, Irinotecan, Gemcitabine and Abraxane.Results: After analyzing different tumor stem cell markers (SOX2, OCT4, CD133, CD44 and CD24) in pancreatic cancer cells treated with different chemotherapeutic protocols by means of RT-qPCR, Oxaliplatin and Gemcitabine in monotherapy were the chemotherapies that selected the most cancer stem cells while the FOLFIRI protocol decreased them.Conclusions: Regarding the selection of markers, it has been much higher in the case of Gemcitabine alone. In conclusion, these findings could improve and personalize pancreatic cancer therapy.
PB Univ granada, editorial
SN 0004-2927
YR 2021
FD 2021-11-24
LK http://hdl.handle.net/10668/21803
UL http://hdl.handle.net/10668/21803
LA en
NO Doello González K, Francisco J.Quiñonero, Perazzoli G, Gago L, Chico M Ángeles, Mesas C. Citotoxicidad diferencial según el régimen de quimioterapia contra las células madre del cáncer de páncreas: estudio preliminar in vitro. Ars Pharm  2021-12- 20;63(1):72-77.
DS RISalud
RD Apr 7, 2025